(EMAILWIRE.COM, August 30, 2018 ) The global primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Growth in the primary cells market is mainly driven by factors such as increasing cancer research; the advantages of primary human cells over cell lines; the increasing demand for monoclonal antibodies; rapid growth in the biotechnology and biopharmaceutical industries, partnerships, collaborations, and acquisitions; and increasing pharmaceutical outsourcing.

Get Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=32854960

The global primary cells market is segmented by origin, type, end user, and region. By origin, the primary cells market is classified into hematopoietic, skin, gastrointestinal, liver, lung, renal, heart, skeletal & muscle, and other primary cells. The liver cells segment is expected to register the highest CAGR during the forecast period due to their increasing demand in toxicological and pharmacological studies.

Drivers
Increasing cancer research
Primary cells are cells isolated from human or animal tissues. These cells are ideal models for cancer biomarker discovery and drug screening. They are also used to understand the biochemical pathways of cellular interactions.

In cancer research, primary cells are often exposed to heavy radiation doses, chemicals, and viruses, which transforms these cells into cancer cells through genetic mutations and the introduction of oncogenes. In this way, the molecular-level mechanism and cause of cancer, as well as the altered signaling pathways of cancerous cells, can be studied.

Advantages of primary human cells over cell lines
Primary human cells have a wide range of advantages over in vitro cell lines; they provide reliable tissue-specific responses in a biologically relevant microenvironment. Drug responses in cell lines may not provide false responses in a cellular context. Moreover, primary human cells are cost-effective and help in reducing expenditure on animal models required for in vivo studies. Pre-screened primary cells help in representing signaling in vivo very closely. Owing to this, pharmaceutical and biotechnology companies as well as CROs are increasingly shifting to primary human cells for their lead identification and optimization processes in drug discovery.

The global primary cells market is dominated by North America, followed by Europe. North America will continue to dominate the global primary cells market during the forecast period, however, Asia is expected to witness the highest CAGR, with the growth in this market centered on China and Japan. Increasing number of players launching new human primary cells for research, expansion of pharmaceutical and biotechnology industries, and increasing prevalence of cancer in the region are the major factors driving the growth of the North American market. However, regulatory concerns regarding primary cell culture contamination will restrain the growth of this market. Some of the major players in the primary cells market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK). These companies have a broad product portfolio with comprehensive features. Key industry players focus on acquisitions to maintain and enhance their position in the primary cells market.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com